Summary
Eli Lilly and Company (LLY) has filed an 8-K report on October 17, 2005, detailing a change in its Board of Directors. Sir John Rose resigned from the board, effective October 14, 2005, citing a need to focus on family and his executive duties at Rolls Royce Group plc. This departure created a vacancy that has been filled by the appointment of J. Erik Fyrwald. Mr. Fyrwald, a Group Vice-President at E. I. du Pont de Nemours and Company with extensive experience in sales, management, and corporate planning across various divisions, including agriculture and engineering polymers, will join the board effective November 1, 2005. He has been appointed to the director class of 2006 and will serve on the compensation and science and technology committees. His background in a related life sciences and agricultural sector is a notable factor for investors.
Key Highlights
- 1Sir John Rose resigned from the Eli Lilly Board of Directors, effective October 14, 2005.
- 2The resignation was due to Sir John Rose's commitment to family and his role as CEO of Rolls Royce Group plc.
- 3J. Erik Fyrwald has been elected to fill the director vacancy, effective November 1, 2005.
- 4Mr. Fyrwald brings significant executive experience from E. I. du Pont de Nemours and Company, including leadership in agriculture and nutrition.
- 5Mr. Fyrwald has been assigned to the director class of 2006.
- 6He has been appointed to the board's compensation and science and technology committees.